To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Preclinical Anti-Integrin αvβ6 Autoantibodies in Ulcerative Colitis: Validation of Predictive Performance, Early Life Emergence and Environmental Modifiers across Multiple Population-Based Cohorts
Thermo Fisher Scientific, Immunodiagnostics, Uppsala, Sweden; Uppsala University, Immunology- Genetics and Pathology, Uppsala, Sweden.
Örebro University, School of Medical Sciences. Department of Laboratory Medicine- Clinical Microbiology.ORCID iD: 0000-0002-4329-1659
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.ORCID iD: 0000-0002-1906-0746
Örebro University, School of Medical Sciences.ORCID iD: 0009-0002-8951-9839
Show others and affiliations
2026 (English)In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 20, no Suppl. 1, p. i76-i78, article id OP32Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Background: IgG autoantibodies against integrin αvβ6 have been associated with preclinical ulcerative colitis (UC),1,2 but data on their emergence and validation are still scarce. Therefore, we aimed to establish and validate a cutoff of anti-αvβ6 for predicting future UC across two independent preclinical cohorts. Additionally, we examined their development in early-life, assessed the influence of genetic-, environmental risk factors and inflammation on anti-αvβ6.

Methods: Within large population-based cohorts (n > 180,000), prediagnostic blood samples from individuals who later in life were diagnosed with UC were compared with age- and sex-matched controls who remained UC-free during follow-up (Figure 1). To explore early-life presence and genetic and shared environmental influences, we analysed serum from ABIS, a population-based birth cohort (n = 17,055) and the Swedish Twin Registry (n > 97,000). Anti-αvβ6 levels were measured using an in-house automated fluorescence enzyme immunoassay. Relative estimates of proteins were measured on the Olink platform3.

Results: In the discovery cohort (Table 1), anti-αvβ6 antibodies differentiated preclinical UC from controls (area under the curve [AUC]=0.68). Applying the model to the validation cohort yielded an AUC of 0.79, with a sensitivity of 46% and a specificity of 93%, at the optimal cut-off (109 UA/l) derived from the discovery cohort. Predictive capacity increased closer to diagnosis but remained significant for samples collected ≥20 years before UC diagnosis (AUC=0.67). In the birth cohort, anti-αvβ6 levels at birth appeared elevated in children who later developed UC (OR = 2.13; 95%CI, 0.84-5.38), likely reflecting transplacental antibody transfer, but also after 5 years (OR = 2.58; 95%CI, 0.83-8.03) and 8 years (OR = 2.50; 95%CI, 0.30-21.00). When assessing the level of agreement within twin pairs, low intra-class correlation coefficients were observed irrespective of zygosity and disease status, suggesting limited influence of genetic and shared environmental exposures. However, anti-αvβ6 levels differed across smoking categories in the preclinical cohorts, but inclusion of smoking status added little to model performance (AUC=0.82). By calculating a composite proteomic score, a progressive increase in the score was observed from the lowest to highest quartile of αvβ6 levels in preclinical UC, whereas most controls were found in the lowest quartiles for both the proteomic score and autoantibody levels.

Conclusion: Anti-αvβ6 autoantibodies represent a reproducible biomarker for preclinical UC. Their early-life presence, environmental modulation, and correlation with immuno-inflammatory proteins highlight their potential utility for risk stratification.

Place, publisher, year, edition, pages
Oxford University Press, 2026. Vol. 20, no Suppl. 1, p. i76-i78, article id OP32
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-127063DOI: 10.1093/ecco-jcc/jjaf231.032ISI: 001667526500001OAI: oai:DiVA.org:oru-127063DiVA, id: diva2:2036218
Conference
21st Congress of ECCO, Stockholm, Sweden, February 18-21, 2026
Available from: 2026-02-06 Created: 2026-02-06 Last updated: 2026-02-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records

Grännö, OlleBergemalm, DanielSalomon, BenitaSalihovic, SamiraEriksson, CarlLindqvist, Carl MårtenRepsilber, DirkHalfvarson, Jonas

Search in DiVA

By author/editor
Grännö, OlleBergemalm, DanielSalomon, BenitaSalihovic, SamiraEriksson, CarlLindqvist, Carl MårtenRepsilber, DirkHalfvarson, Jonas
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Journal of Crohn's & Colitis
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 53 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf